Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, on Friday announced that Chief Medical Officer David Shook will be stepping down and Shawn Rose will take over as CMO and Head of Research and Development, effective June 23.
David Shook is stepping down to seek other opportunities.
Rose has been serving at Vividion Therapeutics, as Chief Development Officer, Immunology.
During the transition, Rose will work with Shook, who will remain on as a consultant through July 11.
Nkarta is currently trading 1.37% higher at $1.8550 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.